Development of cattle TB vaccines based on heterologous prime-boosting strategies

Abstract

Abstract
Development of a TB vaccine for cattle is a research priority in Great Britain. Two challenges need to be addressed. Firstly, vaccine strategies enhancing the efficacy of M. bovis bacille Calmette Guérin (BCG), currently the only potentially available TB vaccine, and secondly the development of a diagnostic test to be used alongside vaccination to differentiate vaccinated and infected animals (DIVA test). Significant progress in developing TB vaccines for cattle has been made over the last 7 years. Specifically: (i) DNA, protein, or viral subunit subunit vaccines used in combination with BCG have been shown to give superior protection against experimental challenge in cattle than BCG (heterologous prime-boost), (ii) neonatal BCG vaccination provides protection, (iii) prototype reagents that allow discrimination between vaccinated and infected animals have been developed; and (iv) and correlates of disease severity have been identified that can predict the success or failure of vaccination. The present overview provides details of some of these advances. [Ethiop.J.Health Dev. 2008;22(Special Issue):100-104]